Autolus Therapeutics (NASDAQ:AUTL) Rating Increased to Buy at The Goldman Sachs Group

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, MarketBeat Ratings reports. The firm currently has a $7.60 price target on the stock, up from their prior price target of $7.00. The Goldman Sachs Group’s target price would suggest a potential upside of 146.75% from the company’s previous close.

AUTL has been the subject of a number of other research reports. Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, November 11th. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $10.15.

Autolus Therapeutics Trading Up 2.3 %

Shares of Autolus Therapeutics stock opened at $3.08 on Monday. Autolus Therapeutics has a 1 year low of $2.94 and a 1 year high of $7.45. The company has a market cap of $819.56 million, a P/E ratio of -2.55 and a beta of 2.04. The stock has a 50-day moving average price of $3.91 and a 200 day moving average price of $3.99.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the business posted ($0.26) earnings per share. On average, equities analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. ProShare Advisors LLC bought a new position in Autolus Therapeutics during the second quarter valued at about $43,000. Capstone Investment Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 3rd quarter valued at about $51,000. Daiwa Securities Group Inc. raised its stake in shares of Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares in the last quarter. Herbst Group LLC acquired a new stake in Autolus Therapeutics in the 3rd quarter worth approximately $91,000. Finally, Bayesian Capital Management LP bought a new stake in Autolus Therapeutics during the first quarter worth approximately $100,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.